Risk for virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014.

Risk for virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014.

Int J Cancer. 2018 Apr 25;:

Authors: Taborelli M, Piselli P, Ettorre GM, Lauro A, Galatioto L, Baccarani U, Rendina M, Shalaby S, Petrara R, Nudo F, Toti L, Sforza D, Fantola G, Cimaglia C, Agresta A, Vennarecci G, Pinna AD, Gruttadauria S, Risaliti A, Di Leo A, Burra P, Rossi M, Tisone G, Zamboni F, Serraino D, Italian Transplant & Cancer Cohort Study

Abstract
This cohort study assessed, in Italy, the overall pattern of risk for de novo malignancies following liver transplantation (LT). The study group included 2832 individuals who underwent LT between 1985 and 2014 in nine centres throughout all of Italy. Person-years (PYs) at cancer risk were computed from 30 days after LT to the date of cancer diagnosis, to the date of death, or to the end of follow-up. Excess cancer risk, as compared to the general population, was estimated using standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). During 18,642 PYs, 246 LT recipients developed 266 de novo malignancies, corresponding to a 1.8-fold higher cancer risk (95% CI: 1.6-2.0). SIRs were particularly elevated for virus-related malignancies, including Kaposi's sarcoma (SIR=53.6, 95% CI: 30.0-88.5), non-Hodgkin lymphomas (SIR=7.1, 95% CI: 4.8-10.1), and cervix uteri (SIR=5.4, 95% CI: 1.1-15.8). Among virus-unrelated malignancies, elevated risks emerged for head and neck (SIR=4.4, 95% CI: 3.1-6.2), oesophagus (SIR=6.7, 95% CI: 2.9-13.3), and adrenal gland (SIR=22.9, 95% CI: 2.8-82.7). Borderline statistically significant elevated risks were found for lung cancer (SIR=1.4, 95% CI: 1.0-2.1) and skin melanoma (SIR=2.6, 95% CI: 1.0-5.3). A reduced risk emerged for prostate cancer (SIR=0.1, 95% CI: 0.0-0.5). These findings underline the need of preventive interventions and early detection of malignancies, specifically tailored to LT recipients. This article is protected by copyright. All rights reserved.

PMID: 29693248 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader https://ift.tt/2qXYIdm